Erasca (ERAS) Competitors $1.52 -0.01 (-0.65%) Closing price 04:00 PM EasternExtended Trading$1.53 +0.01 (+0.59%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. CDTX, TWST, TVTX, BHVN, AUPH, SDGR, EVO, JANX, ETNB, and EWTXShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Cidara Therapeutics (CDTX), Twist Bioscience (TWST), Travere Therapeutics (TVTX), Biohaven (BHVN), Aurinia Pharmaceuticals (AUPH), Schrodinger (SDGR), Evotec (EVO), Janux Therapeutics (JANX), 89BIO (ETNB), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Its Competitors Cidara Therapeutics Twist Bioscience Travere Therapeutics Biohaven Aurinia Pharmaceuticals Schrodinger Evotec Janux Therapeutics 89BIO Edgewise Therapeutics Erasca (NASDAQ:ERAS) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts recommend ERAS or CDTX? Erasca currently has a consensus target price of $4.29, indicating a potential upside of 181.95%. Cidara Therapeutics has a consensus target price of $64.14, indicating a potential upside of 4.31%. Given Erasca's higher possible upside, equities analysts plainly believe Erasca is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media prefer ERAS or CDTX? In the previous week, Erasca had 6 more articles in the media than Cidara Therapeutics. MarketBeat recorded 11 mentions for Erasca and 5 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 0.54 beat Erasca's score of 0.15 indicating that Cidara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cidara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ERAS or CDTX? Erasca has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Is ERAS or CDTX more profitable? Erasca's return on equity of -31.19% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -31.19% -26.34% Cidara Therapeutics N/A -50.81%-42.46% Which has stronger earnings & valuation, ERAS or CDTX? Cidara Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.45-3.38Cidara TherapeuticsN/AN/A-$169.83M-$11.13-5.52 Do institutionals and insiders believe in ERAS or CDTX? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 14.4% of Erasca shares are owned by company insiders. Comparatively, 3.9% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryErasca beats Cidara Therapeutics on 9 of the 14 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$431.18M$3.07B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-3.3820.4830.7825.12Price / SalesN/A355.18456.64116.46Price / CashN/A41.5625.2228.45Price / Book1.019.549.375.95Net Income-$161.65M-$54.74M$3.26B$265.46M7 Day Performance-2.56%2.39%1.88%0.96%1 Month Performance1.33%4.60%3.73%2.47%1 Year Performance-44.73%9.17%28.93%20.24% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.3431 of 5 stars$1.52-0.7%$4.29+182.0%-45.4%$431.18MN/A-3.38120News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionCDTXCidara Therapeutics3.5082 of 5 stars$62.00flat$64.14+3.5%+394.4%$1.57B$1.27M-5.5790TWSTTwist Bioscience4.0681 of 5 stars$27.63+7.8%$49.40+78.8%-35.7%$1.55B$312.97M-19.06990Positive NewsTVTXTravere Therapeutics2.56 of 5 stars$17.28+2.0%$32.21+86.4%+116.2%$1.51B$233.18M-8.47460Analyst UpgradeBHVNBiohaven3.7938 of 5 stars$13.42-8.9%$58.46+335.5%-58.5%$1.51BN/A-1.43239Trending NewsAnalyst ForecastAUPHAurinia Pharmaceuticals2.9246 of 5 stars$11.43+0.5%$12.00+5.0%+95.2%$1.50B$235.13M26.58300Positive NewsSDGRSchrodinger3.1801 of 5 stars$18.63-3.0%$32.75+75.8%+1.6%$1.41B$207.54M-7.51790Analyst ForecastEVOEvotec1.7739 of 5 stars$3.81-3.1%$5.90+54.9%+12.9%$1.40B$862.40M0.004,827Analyst RevisionJANXJanux Therapeutics2.7186 of 5 stars$22.67-0.7%$91.89+305.3%-38.2%$1.37B$10.59M-12.5930Analyst ForecastETNB89BIO1.9485 of 5 stars$8.77-4.3%$26.29+199.7%+17.4%$1.34BN/A-2.4340News CoverageEWTXEdgewise Therapeutics2.2945 of 5 stars$12.99+2.4%$41.60+220.2%-24.1%$1.34BN/A-8.3860Analyst Forecast Related Companies and Tools Related Companies Cidara Therapeutics Alternatives Twist Bioscience Alternatives Travere Therapeutics Alternatives Biohaven Alternatives Aurinia Pharmaceuticals Alternatives Schrodinger Alternatives Evotec Alternatives Janux Therapeutics Alternatives 89BIO Alternatives Edgewise Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access